Aardvark Therapeutics

Rethinking Metabolic Health

San Diego, United States · Founded 2017 · $114.0M raised

Employees
11–50
Founded
2017
Business Model
B2B
Total Funding
$114.0M
Last Round
$85.0M Series CMay 2024
Rounds
2

About

Aardvark Therapeutics is a clinical-stage biopharmaceutical company developing novel, small-molecule therapies designed to inhibit hunger and treat metabolic diseases. Its lead compound, ARD-101, is an oral investigational drug that activates bitter taste receptors (TAS2Rs) in the digestive tract to trigger the local release of satiety hormones and suppress hunger. The company is focused on conditions including hyperphagia in rare diseases such as Prader-Willi Syndrome as well as general obesity, with the goal of becoming a leader in the treatment of hunger-associated metabolic disorders.

Summary

Aardvark Therapeutics is a Biotech company based in San Diego, United States, founded in 2017. It has raised $114.0M in total across 2 rounds, most recently a $85.0M Series C round in May 2024. Investors include Decheng Capital, Cormorant Asset Management and Surveyor Capital.

Tech & App Stack

4 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Series CSeries CMay 2024
$85.0M

Sign up to see all 2 rounds

Series B through Series C — per-round amounts, valuations, and who invested in each round.

Investors

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Aardvark Therapeutics on Indexed.vc
<a href="https://indexed.vc/companies/aardvark-therapeutics"><img src="https://indexed.vc/api/badge/company/aardvark-therapeutics" alt="Aardvark Therapeutics on Indexed.vc" width="260" height="76" /></a>